Brief: Corline Biomedical Gets Positive Feedback From FDA Regarding Co's Planned Phase 2 Study
Dec 4 (Reuters) - Corline Biomedical AB CLBIO.ST :
* FDA GIVES POSITIVE FEEDBACK REGARDING CO'S PLANNED PHASE 2
STUDY
* IS ALSO GIVEN POSSIBILITY TO CARRY OUT ITS PHASE 2 STUDY
WITH
CLINICAL TRIAL SITES ONLY IN EUROPE WHICH WILL REDUCE COSTS AND
DURATION FOR PHASE 2 CONSIDERABLY
Source text for Eikon: ID:nGNE3jl8Yp
Further company coverage: CLBIO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln